PTS injection for stage 4 lung cancer without gene mutations
Part of Cancer, Lungs & breathing clinical trials.
This trial tests injecting a drug called PTS directly into lung tumors for people with stage 4 non-small cell lung cancer that doesn't have certain gene changes. It is for patients whose tumors have stayed stable after first-line treatment and are located in a small area of the outer lung.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage 4 non-small cell lung cancer without a driver gene mutation (like EGFR or ALK).
- You have at least one lung tumor that can be injected, is 5 cm or smaller, and is in the outer part of the lung.
- Your tumor has stayed stable after your first line of treatment with chemo and immunotherapy.
- You are in good general health with normal liver, kidney, and heart function.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (T cells) that are specially trained to find and attack lung cancer cells. It may help people with advanced or relapsed lung cancer who have not improved with standard treatments.
This trial tests a new cell therapy called BST08, made from your own immune cells, for advanced non-small cell lung cancer that has not responded to at least two standard treatments. The goal is to see if this therapy is safe and can help shrink tumors.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new drug called TQB6411 for people with lung cancer that can be measured by scans. The drug is given by injection, and the study will see if it is safe and if it helps shrink or control the cancer.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.